DMP evaluation reports
The Federal Joint Comitee (G-BA) as well as the authorising health insurance companies have published the first evaluation report on the indication BK (breast cancer) 2022.
The Federal Joint Comitee (G-BA) as well as the authorising health insurance companies have published the first evaluation report on the indication BK (breast cancer) 2022.
The Federal Joint Comitee (G-BA) as well as the authorising health insurance companies have published the evaluation report on the indication DM1 2022.
The Federal Joint Comitee (G-BA) as well as the authorising health insurance companies have published the evaluation report on the indication DM2 2021.
The Federal Joint Comitee (G-BA) as well as the authorising health insurance companies have published the first evaluation report on the indication ASB 2020.